Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the Comparative Toxicogenomics

Allan Peter Davis1, Thomas C Wiegers1, Benjamin L King2

  • 1Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina, United States of America.

Plos One
|May 13, 2016
PubMed

Insights

Researchers integrated public databases to uncover shared molecular events across diseases. This approach aids in understanding disease origins and developing new treatments by linking gene functions to various conditions.

Area of Science:

  • Genomics
  • Toxicology
  • Bioinformatics
  • Computational Biology

Background:

  • Discovering common molecular events across diseases can advance etiological understanding and treatment strategies.
  • Publicly available curated datasets offer a valuable resource for such discoveries.

Purpose of the Study:

  • To integrate data from the Comparative Toxicogenomics Database (CTD) with Gene Ontology (GO) annotations to create a novel resource for exploring disease relationships.
  • To demonstrate the utility of this resource in identifying disease similarities, predicting drug repositioning candidates, and generating therapeutic hypotheses.

Main Methods:

  • Manually curated chemical-gene, chemical-disease, and gene-disease interactions from CTD were combined with NCBI Gene's GO-gene annotations.
  • A large-scale inference set of GO terms and diseases was generated.
  • Applications included analyzing drug repositioning, predicting disease similarities, and identifying potential drug candidates for specific cancers.

Main Results:

  • Generated over 753,000 inferences linking 15,700 GO terms to 4,200 diseases.
  • Demonstrated that diseases targeted by repositioned drugs show greater similarity when analyzed via GO terms compared to genes alone.
  • Predicted and validated novel disease-disease similarities (e.g., stomach ulcers and atherosclerosis with bipolar disorder).
  • Identified potential drug candidates, including cisplatin and JQ1, for B-cell chronic lymphocytic leukemia.

Conclusions:

  • The integrated CTD and GO dataset provides a powerful resource for researchers to explore disease pathologies and molecular underpinnings.
  • This resource facilitates the identification of common disease mechanisms, potential therapeutic targets, new drug indications, comorbidities, and potential side effects.
  • The findings support the use of integrated biological data for advancing drug discovery and understanding complex diseases.

Related Concept Videos

Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
41.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
136
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
124
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
86